MX375281B - Particulas de fenilefrina y su uso en formulaciones farmaceuticas. - Google Patents

Particulas de fenilefrina y su uso en formulaciones farmaceuticas.

Info

Publication number
MX375281B
MX375281B MX2015012635A MX2015012635A MX375281B MX 375281 B MX375281 B MX 375281B MX 2015012635 A MX2015012635 A MX 2015012635A MX 2015012635 A MX2015012635 A MX 2015012635A MX 375281 B MX375281 B MX 375281B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
phenylephrine particles
phenylephrine
particles
solid
Prior art date
Application number
MX2015012635A
Other languages
English (en)
Other versions
MX2015012635A (es
Inventor
Vincent Chen
Der-Yang Lee
Robert Shen
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of MX2015012635A publication Critical patent/MX2015012635A/es
Publication of MX375281B publication Critical patent/MX375281B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen las partículas de fenilefrina adecuadas para formas farmacéuticas sólidas, semisólidas o líquidas.
MX2015012635A 2013-03-15 2014-02-28 Particulas de fenilefrina y su uso en formulaciones farmaceuticas. MX375281B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/832,797 US20140271893A1 (en) 2013-03-15 2013-03-15 Coated phenylephrine particles and use thereof in pharmaceutical formulations
PCT/US2014/019311 WO2014149529A1 (en) 2013-03-15 2014-02-28 Coated phenylephrine particles and use thereof in pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2015012635A MX2015012635A (es) 2016-08-03
MX375281B true MX375281B (es) 2025-03-06

Family

ID=50288314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012635A MX375281B (es) 2013-03-15 2014-02-28 Particulas de fenilefrina y su uso en formulaciones farmaceuticas.

Country Status (17)

Country Link
US (1) US20140271893A1 (es)
EP (1) EP2968188B1 (es)
JP (1) JP6373957B2 (es)
CN (1) CN105246466B (es)
AR (1) AR095526A1 (es)
AU (1) AU2014238062B2 (es)
BR (1) BR112015022945B1 (es)
CA (1) CA2906363C (es)
IL (1) IL241051B (es)
MX (1) MX375281B (es)
NZ (1) NZ712318A (es)
PH (1) PH12015502015B1 (es)
RU (1) RU2681312C2 (es)
SA (1) SA515361065B1 (es)
UA (1) UA120251C2 (es)
WO (1) WO2014149529A1 (es)
ZA (1) ZA201507676B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
AU736308B2 (en) 1996-12-20 2001-07-26 Warner-Lambert Company Llc Antitussive drugs delivered by ion exchange resins
CA2404687A1 (en) * 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
WO2007011705A2 (en) 2005-07-14 2007-01-25 University Of Notre Dame Du Lac Response time detection in a network having shared interfaces
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
MX2008015358A (es) 2006-06-01 2009-03-06 Schering Corp Composiciones farmaceuticas para liberacion sostenida de fenilefrina.
JP2009541337A (ja) * 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド 活性成分を含有する腸溶性の被覆された粒子
BRPI0719021A2 (pt) 2006-11-21 2013-12-17 Mcneil-Ppc, Inc. Suspensões analgésicas de liberação modificada.
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
RU2011102777A (ru) * 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
AU2011288413B2 (en) * 2010-08-13 2014-05-22 Mundipharma Pty Limited Use of binders for manufacturing storage stable formulations
RU2477741C1 (ru) * 2012-04-27 2013-03-20 Юрий Васильевич Захаров Состав мульчирующего покрытия (варианты)

Also Published As

Publication number Publication date
EP2968188A1 (en) 2016-01-20
PH12015502015A1 (en) 2016-01-11
UA120251C2 (uk) 2019-11-11
EP2968188B1 (en) 2017-04-19
JP6373957B2 (ja) 2018-08-15
AU2014238062B2 (en) 2018-11-29
RU2681312C2 (ru) 2019-03-06
US20140271893A1 (en) 2014-09-18
ZA201507676B (en) 2017-11-29
CA2906363C (en) 2021-03-16
SA515361065B1 (ar) 2017-02-02
HK1219886A1 (en) 2017-04-21
BR112015022945A8 (pt) 2022-07-26
CN105246466A (zh) 2016-01-13
PH12015502015B1 (en) 2016-01-11
MX2015012635A (es) 2016-08-03
WO2014149529A1 (en) 2014-09-25
AR095526A1 (es) 2015-10-21
IL241051A0 (en) 2015-11-30
IL241051B (en) 2018-06-28
JP2016516029A (ja) 2016-06-02
CA2906363A1 (en) 2014-09-25
BR112015022945B1 (pt) 2022-11-01
NZ712318A (en) 2020-05-29
RU2015144045A (ru) 2017-04-20
BR112015022945A2 (pt) 2017-07-18
CN105246466B (zh) 2018-03-30
AU2014238062A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2021001231A (es) Compuestos heterociclicos y sus usos.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
BR112016020618A2 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
MX379312B (es) Anticuerpos especificos para fcrn.
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2017007596A (es) Procedimiento para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina; y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.
UA116372C2 (uk) Частинки резинату фенілефрину
MX2015012635A (es) Particulas de fenilefrina y su uso en formulaciones farmaceuticas.

Legal Events

Date Code Title Description
FG Grant or registration